ALX Oncology (ALXO) Competitors

$1.96 -0.04 (-1.75%)

As of 01:06 PM Eastern

ALXO vs. DBVT, EVO, SEPN, SVRA, and CVAC

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include DBV Technologies (DBVT), Evotec (EVO), Septerna (SEPN), Savara (SVRA), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

How does ALX Oncology compare to DBV Technologies?

ALX Oncology (NASDAQ:ALXO) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

ALX Oncology has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
DBV Technologies	$5.64M	196.26	-$146.95M	-$4.46	N/A

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ALX Oncology has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. ALX Oncology's return on equity of -124.06% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

ALX Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market.

In the previous week, ALX Oncology had 9 more articles in the media than DBV Technologies. MarketBeat recorded 13 mentions for ALX Oncology and 4 mentions for DBV Technologies. ALX Oncology's average media sentiment score of 1.11 beat DBV Technologies' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 134.10%. DBV Technologies has a consensus price target of $40.25, indicating a potential upside of 115.30%. Given ALX Oncology's higher probable upside, equities analysts clearly believe ALX Oncology is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

ALX Oncology beats DBV Technologies on 13 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Evotec?

Evotec (NASDAQ:EVO) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Evotec currently has a consensus target price of $7.00, indicating a potential upside of 155.01%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 134.10%. Given Evotec's higher possible upside, equities research analysts plainly believe Evotec is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.09	-$117.12M	N/A	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

ALX Oncology has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
ALX Oncology	N/A	-124.06%	-85.57%

In the previous week, ALX Oncology had 11 more articles in the media than Evotec. MarketBeat recorded 13 mentions for ALX Oncology and 2 mentions for Evotec. ALX Oncology's average media sentiment score of 1.11 beat Evotec's score of 0.14 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ALX Oncology beats Evotec on 8 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Septerna?

ALX Oncology (NASDAQ:ALXO) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Septerna has higher revenue and earnings than ALX Oncology. Septerna is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Septerna	$45.95M	26.36	-$48.88M	-$0.81	N/A

98.0% of ALX Oncology shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 4.3% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ALX Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Septerna has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

In the previous week, Septerna had 3 more articles in the media than ALX Oncology. MarketBeat recorded 16 mentions for Septerna and 13 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.11 beat Septerna's score of -0.32 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Septerna	-49.88%	-12.72%	-8.87%

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 134.10%. Septerna has a consensus price target of $43.13, suggesting a potential upside of 60.53%. Given ALX Oncology's higher probable upside, equities analysts plainly believe ALX Oncology is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Septerna beats ALX Oncology on 10 of the 16 factors compared between the two stocks.

How does ALX Oncology compare to Savara?

ALX Oncology (NASDAQ:ALXO) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 134.10%. Savara has a consensus target price of $9.13, suggesting a potential upside of 91.90%. Given ALX Oncology's higher probable upside, equities research analysts clearly believe ALX Oncology is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ALX Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, Savara had 5 more articles in the media than ALX Oncology. MarketBeat recorded 18 mentions for Savara and 13 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.11 beat Savara's score of -0.79 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Savara's return on equity of -87.19% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Savara	N/A	-87.19%	-66.42%

Savara is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

ALX Oncology and Savara tied by winning 7 of the 14 factors compared between the two stocks.

How does ALX Oncology compare to CureVac?

CureVac (NASDAQ:CVAC) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CureVac has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, ALX Oncology had 13 more articles in the media than CureVac. MarketBeat recorded 13 mentions for ALX Oncology and 0 mentions for CureVac. ALX Oncology's average media sentiment score of 1.11 beat CureVac's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
ALX Oncology	Positive

CureVac currently has a consensus price target of $6.83, suggesting a potential upside of 46.64%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 134.10%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

CureVac has a net margin of 199.92% compared to ALX Oncology's net margin of 0.00%. CureVac's return on equity of -23.03% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
ALX Oncology	N/A	-124.06%	-85.57%

Summary

CureVac beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$264.41M	$3.27B	$6.28B	$12.14B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-1.32	18.56	20.61	25.12
Price / Sales	N/A	282.45	581.13	92.21
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	4.09	6.60	9.74	6.62
Net Income	-$101.69M	$24.30M	$3.55B	$335.39M
7 Day Performance	-3.20%	-3.08%	-1.79%	-1.72%
1 Month Performance	17.66%	-7.43%	-3.65%	-1.61%
1 Year Performance	355.60%	52.73%	29.85%	27.79%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	3.8923 of 5 stars	$1.97 -1.8%	$4.60 +134.1%	+357.2%	$264.41M	N/A	N/A	40	Positive News
DBVT DBV Technologies	2.2966 of 5 stars	$20.36 +3.2%	$40.25 +97.7%	+68.9%	$1.10B	$5.64M	N/A	80
EVO Evotec	2.9641 of 5 stars	$3.06 -0.3%	$7.00 +128.8%	-32.5%	$1.09B	$891.97M	N/A	4,553
SEPN Septerna	3.1615 of 5 stars	$23.57 -1.3%	$43.13 +83.0%	+167.3%	$1.07B	$45.95M	N/A	N/A	Earnings Report Upcoming Earnings
SVRA Savara	2.3137 of 5 stars	$5.12 -2.1%	$9.13 +78.2%	+59.9%	$1.07B	N/A	N/A	20	Positive News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. DBVT, EVO, SEPN, SVRA, and CVAC

How does ALX Oncology compare to DBV Technologies?

Summary

How does ALX Oncology compare to Evotec?

Summary

How does ALX Oncology compare to Septerna?

Summary

How does ALX Oncology compare to Savara?

Summary

How does ALX Oncology compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. DBVT, EVO, SEPN, SVRA, and CVAC

How does ALX Oncology compare to DBV Technologies?

Which has better valuation and earnings, ALXO or DBVT?

Do insiders & institutionals believe in ALXO or DBVT?

Is ALXO or DBVT more profitable?

Which has more risk & volatility, ALXO or DBVT?

Does the media refer more to ALXO or DBVT?

Do analysts prefer ALXO or DBVT?

Summary

How does ALX Oncology compare to Evotec?

Do analysts recommend EVO or ALXO?

Which has preferable valuation and earnings, EVO or ALXO?

Which has more volatility and risk, EVO or ALXO?

Is EVO or ALXO more profitable?

Does the media prefer EVO or ALXO?

Do institutionals and insiders have more ownership in EVO or ALXO?

Summary

How does ALX Oncology compare to Septerna?

Which has higher valuation & earnings, ALXO or SEPN?

Do insiders and institutionals have more ownership in ALXO or SEPN?

Which has more risk & volatility, ALXO or SEPN?

Does the media refer more to ALXO or SEPN?

Is ALXO or SEPN more profitable?

Do analysts recommend ALXO or SEPN?

Summary

How does ALX Oncology compare to Savara?

Do analysts recommend ALXO or SVRA?

Do insiders & institutionals hold more shares of ALXO or SVRA?

Which has more volatility & risk, ALXO or SVRA?

Does the media refer more to ALXO or SVRA?

Is ALXO or SVRA more profitable?

Which has preferable earnings and valuation, ALXO or SVRA?

Summary

How does ALX Oncology compare to CureVac?

Which has more risk and volatility, CVAC or ALXO?

Do institutionals and insiders hold more shares of CVAC or ALXO?

Which has higher earnings & valuation, CVAC or ALXO?

Does the media favor CVAC or ALXO?

Do analysts recommend CVAC or ALXO?

Is CVAC or ALXO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools